In October 2025, Northwest Biotherapeutics completed the purchase of Advent BioServices Ltd., the licensed GMP operator of the Sawston facility. Advent’s audited 2023 accounts at UK Companies House reported £20 million turnover and £25 million in assets, making it the only fully digital, MHRA-licensed GMP cell-therapy manufacturer in the UK. NW Bio paid about £1.4 million in cash and assumed £9–10 million in liabilities; no new shares were issued, and about 19 million Advent-held shares were cancelled.
In practical terms, she gifted shareholders the only digital, MHRA-licensed GMP cell-therapy facility in the UK and full ownership of a world-class, regulator-approved manufacturing platform.
The only people conflicted here are the shorts.
Bullish
Market Data 
Markets 
AI
